ABSTRACT
Basic Features of Picornaviridae Biology
human enteroviruses are single-stranded, non-enveloped RnA viruses belonging to the Picornaviridae family. the RnA strand is coding (positive) and is embedded into an icosahedral capsid made of 60 copies each of the VP1, VP2, VP3 and VP4 proteins (22) . infections with enteroviruses are very common, only second to infections with another group of members of the Picornaviridae family -namely, the rhinoviruses, and may produce a spectrum of clinical outcomes, ranging from asymptomatic infection, to mild upper respiratory illness, to aseptic meningitis, myocarditis, pericarditis, and -in case of neonates and very young children -severe, occasionally fatal disease (13) . the role of enteroviral infection in triggering development of diabetes type i in susceptible children is considered to be quite definite (21, 30) . Immunocompromised patients are another group specifically at risk of suffering long-lasting consequences of infections with enteroviruses. To date, there is no specific antiviral therapy or vaccine either against rhinoviruses or most enteroviruses, apart from the happy exception of the vaccine against the poliomyelitis virus, another member of the genus Enterovirus. it seems that this area of research still leaves much to be desired, as most picornaviruses seem to develop resistance quite effectively against almost anything that science can offer at the moment. this impressive adaptive capacity presents quite a challenge to modern healthcare and as of now it seems that this may very well continue for some time to come, as the ability to become resistant to antiviral drugs stems inherently from the biology of picornaviruses.
Structure of Picornaviridae genome and capsid proteins
the genome of picornaviruses is organized similarly (albeit not identically) across the family and comprises usually 7 200-8 500 nucleotides (11, 20) . there is a single open reading frame flanked at both ends by untranslated regions, the 5'-UtR being fairly long. the viral genome is translated into a single polyprotein precursor, containing one structural and two non-structural domains, which is subsequently cleaved into mature protein products by proteases encoded within the viral genome. the VP1-4 mature proteins are produced by the proteolytic cleavage of the n-terminus of the precursor protein, the products never actually becoming physically separated (20, 28) . VP1-3 proteins essentially have the same basic structure, a beta-barrel consisting of eight β-strands linked by loops of variable length. VP1 is the most externally located protein in the virion, and is therefore considered to be the most important viral antigen of all picornavirus capsid proteins (22) . it also shows the greatest variability among all VP proteins, as the structure is conserved, but the amino acid residues building it are not.
Picornaviruses may bind to a variety of target cell receptors, depending on the particular virus and the type of the cell undergoing infection. capsid proteins VP1-3 form a 'canyon' on the surface of the virion, a structure that binds to the relevant surface receptor of the host cell. the conformation of the capsid 'canyon' is an important determinant in virus-cell interactions, as binding into the canyon destabilizes the viral particle, triggering uncoating.
Stabilization of the viral capsid via pocket factors
in order to be able to infect host cells while retaining the capacity of the viral particle to remain stable while outside the host cell, the viral proteins maintaining the integrity of the virions need to be capable of considerable conformational change (sometimes also called 'breathing' of the capsid). The latter would allow for the proper uncoating of the virus during infection phase as well as for the correct assembly of the viral particle after the replication of the viral nucleic acid and synthesis of the viral proteins are complete. Viral uncoating is modulated by several mechanisms. Among these are modifications of some of the capsid proteins (namely, VP4) allowing them to 'anchor' onto the membrane of the host cell (2) and ph-dependent mechanisms of extrusion of the viral RnA when the acidity of the environment is altered (e.g. when inside an endocytotic vesicle) (5) . no less (and, probably, more) important is the role played by the so-called hydrophobic pockets in the proteins forming the viral capsid. the mentioned above beta-barrel structure of the VP1-3 proteins forms a hydrophobic 'pocket' in the VP1 protein, which is actually accessible from the surface. the pocket is made of amino acid residues with nonpolar side chains, that, in virions that are not currently participating in infection, may bind and retain hydrophobic molecules (pocket factors) that seat in the interior of the VP1 beta barrel and serve to stabilize the capsid so as to maintain the integrity of the viral particle when not participating in infection (8) . Pocket factors are usually sphingosine-like molecules or fatty acids of variable chain length (e.g. palmitate, myristate) (26) .
in order for the viral nucleic acid to be uncoated, the pocket factor has to be removed. if the viral capsid is overly stable for any reason, subsequent uncoating may prove difficult. The viral protein VP1 forms the floor of the so-called 'canyon' on the surface of the virion, which binds to the target receptor of the cells being infected. the binding of the receptor inside the canyon triggers a conformational change in the viral particle so that the viral nucleic acid could be uncoated. obviously, the 'canyon' must be unoccupied and conformationally adequate to the target receptor. When a natural pocket-binding factor or a synthetic substitute is bound with high affinity inside the hydrophobic pocket of VP1, the conformation of the 'canyon' would not match the target receptor, which results in inhibition of the viral uncoating, thus diminishing the infection potential of the virus (10, 23).
Molecular bases of resistance and dependence of picornaviruses to pocket-binding antivirals
it is only natural that viruses with RnA genome show much higher mutation rates than the DnA viruses because of the error rate of the enzymes involved in RnA replication and the higher risk of introducing stable changes in single-stranded genomes. Divergence within a single enteroviral serotype is significant, up to 25% difference in the nucleotide sequence, or 12% difference in the corresponding amino acid sequence (18) . Such variability allows the virus to adapt to whatever environment it is placed in; therefore, it is not surprising that picornaviruses acquire resistance to most antiviral agents relatively quickly.
What is more, some strains of picornaviruses are capable of escaping neutralization by monoclonal antibodies, usually mediated by substitutions of defined amino acid residues of the capsid, generally ones located in the loops exposed to the capsid surface (12) .
A number of compounds with variable nature have been identified that bind tightly within the hydrophobic 'pocket' of VP1, stabilizing the virion and, respectively, inhibiting the heat-and ph-dependent uncoating of the viral RnA (9, 23, 25) . 'Pocket-stabilizing' chemotherapeutics actually were thought to represent potential agents for etiotropic therapy of such common infections as those caused by rhinoviruses and coxsackieviruses. Unfortunately, Picornaviridae, thanks to their inherent mutability, have an ample potential for evading any of the contemporary therapies, especially the ones that are not virucidal, but, rather, virustatic, as the compounds stabilizing the hydrophobic pocket of VP1 are.
A significant number of 'pocket-retained' compounds have been tested in vitro for their antiviral properties. Among those are naturally occurring compounds, such as flavanoids and flavonoids (3(2H)-isoflavene (C2) and 6-chloro-3(2H)-isoflavene (C10)) (24) as well as synthetically created drugs. Among the synthetic inhibitors of uncoating of picornaviruses the Win family of pocket-binding compounds is prominent, even though now this prominence has mostly historical importance. the Win pocket-binding antivirals comprise a number of pyrazole compounds (e.g., Pleconaril, Arildone and Disoxaril) (19, 31) . these seem to possess rather potent antiviral activity in vitro, but resistance to the drug rapidly develops in vitro as well as in vivo (1, 29) . it has been shown in rhinoviruses as well as in enteroviruses that the mutations that grant the resistance to Win antivirals map to only several of the amino acid residues that form the interior of the ligand-binding pocket (4, 15, 16, 17) . the identity of the amino acid residues that constitute this pocket shows a significant correlation with the susceptibility of the virus to the antiviral action of Win compounds. Basically, the side chains of these were reported to be replaced by bulkier groups (e.g., cys-to-trp, cys-to-tyr or Val-to-leu), thus hindering the entry or the binding of drug within the binding pocket (4); or aromatic side groups were replaced by non-aromatic or vice versa, possibly disrupting the 3-D shape of the binding pocket (15, 16, 17) .
later, it was shown that the persistent presence of synthetic high-affinity pocket-binding agents may actually cause the emergence of viral strains dependent on the drug, that is, largely unable to sustain stable viral particles in the absence of the pocket-binding agent. this is generally related to lasting changes within the pocket forcing the virions to undergo rapid decay when the pocket-binding agent is not present. Usually these dependent mutants are thermolabile, that is, they cannot sustain the capsid at temperatures higher than 37 °c without the presence of a pocket stabilizer (7, 14) . in 2007, Katpally and Smith (6) proposed that at least in certain groups of picornaviruses, namely, the rhinoviruses; it was rather the structure of the hydrophobic pocket itself and not the pocket factor that was crucial for the capsid dynamics, deeming the potential of future development of elaborate new pocket-binding drugs to be uncertain, at best. the risk for rapidly developing resistance coupled with the propensity for actually forming drug-dependent mutants actually brought about an eclipse of the hopes associated with pyrazole Win-compounds as antiviral agents against rhino-and enteroviruses.
Pocket stabilizer antivirals do not seem to be hitting the pharmaceutical market soon, despite the extensive clinical trials
There have been two applications for Pleconaril (SanofiAventis, currently Sanofi S.A.) to the US Food and Drugs Administration so far for use of the compound in humans as an agent against common cold and rhinovirus-aggravated asthma. The first was submitted by ViroPharma Inc. in 2001, but the application was deferred because of concerns over the safety of the drug. The second application to the FDA was filed by Schering-Plough (currently Merck & Co.) five years after the first, in 2006. There have been at least two double-blind, randomized, placebo-controlled trials of the use of pleconaril in adults reporting the efficacy and the safety of the drug when used against the common cold and a Phase ii clinical trial of Pleconaril along with two other capsid stabilizer drugs, BtA-798 and V-073, was reportedly completed in 2007 (3). Pleconaril, however, was still listed as 'product in development' in Oct. 2009, several weeks before Schering-Plough was merged with Merck 7 co. currently, the clinical trials of Pleconaril and BtA-798 in sepsis caused by enteroviruses and rhinovirusinduced exacerbation of pre-existing asthma or coPD are still ongoing, according to reports (27) . neither the generic drug, nor any of the related Win compounds have been licensed by the FDA yet, regardless of the repetitive and lengthy clinical trials. Apparently, the search for means of prevention of infection or an etiotropic cure for the 'common cold', the aseptic meningitis, the enterovirus-induced sepsis and other human conditions related to infections with picornaviruses is still very much ongoing.
